Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 5, 2011, Pages 295-300

  Viazis, Nikos ^a   Karamanolis, George ^b   Vienna, Eleni ^c   Karamanolis, Dimitrios G ^c  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Department of Pyschiatry   (United States)

Author keywords

Gastroesophageal reflux disease; Hypersensitive esophagus; Selective serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; IMIPRAMINE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HYPERSENSITIVE ESOPHAGUS; PRIORITY JOURNAL; REVIEW; THORAX PAIN; TREATMENT DURATION;

EID: 80052360451     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11409279     Document Type: Review

References (34)

1. Bredenoord A. Weusten B. Smout A. (2005) Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 54: 1810–1817.
2. Broekaert D. Fischler B. Sifrim D. Janssens J. Tack J. (2006) Influence of citalopram, a selective serotonin selective-serotonin reuptake inhibitor, on oesophageal hypersensitivity: A double-blind, placebo-controlled study. Aliment Pharmacol Ther 23: 365–370.
3. Cannon R. Quyyumi A. Mincemoyer R. Stine A. Gracely R. Smith W. et al (1994) Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 330: 1411–1419.
4. Charbel S. Khandwala F. Vaezi M. (2005) The role of esophageal monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 100: 283–289.
5. Clouse R. Lustman P. Eckert T. Ferney D. Griffith L. (1998) Low dose trazodone for symptomatic patients with esophageal contraction abnormalities. Gastroenterology 92: 1027–1036.
6. Dent J. Brun J. Fendrick A. Fennerty M. Janssens J. Kahrilas P. et al (1999) An evidence-based appraisal of reflux disease management: The Genval Workshop Report. Gut 44: S1–S16.
7. Fass R. Fennerty M. Vakil N. (2001) Non-erosive reflux disease (NERD) – current concepts and dilemmas. Am J Gastroenterol 96: 303–314.
8. Fass R. Tougas G. (2002) Functional heartburn: The stimulus, the pain and the brain. Gut 51: 885–892.
9. Gebhart G. (2000) Visceral pain – peripheral sensitisation. Gut 47: iv54–iv55.
10. Gershon M. Tack J. (2007) The serotonin signalling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397–414.
11. Goyal R. Hirano I. (1996) The enteric nervous system. N Engl J Med 334: 1106–1115.
12. Grundy D. Scratcherd T. (1989) Sensory afferents from the gastrointestinal tract. In: Ed. Schultz S. Wood J. Rauner B. (eds) Handbook of Physiology Vol. 1 Oxford University: New York, 593–620.
13. Handa M. Mine K. Yamamoto H. Hayashi H. Tsuchida O. Kanazawa F. et al (1999) Antidepressant treatment of patients with diffuse esophageal spasm: A psychosomatic approach. J Clin Gastroenterol 28: 228–232.
14. Hollerbach S. Bulat R. May A. Kamath M. Upton A. Fallen E. et al (2000) Abnormal cerebral processing of oesophageal stimuli in patients with noncardiac chest pain (NCCP). Neurogastroenterol Mot 12: 555–565.
15. Hong S. Vaezi M. (2009) Gastroesophageal reflux monitoring: pH (catheter and capsule) and impedance. Gastrointest Endoscopy Clin N Am 19: 1–22.
16. Hungin A. Hill C. Raghunath A. (2009) Systematic review: Frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 30: 331–342.
17. Kahrilas P. (1996) Gastroesophageal reflux disease. JAMA 276: 983–988.
18. Kim D. Camilleri M. (2000) Serotonin: A mediator of the brain–gut connection. Am J Gastroenterol 95: 2698–2709.
19. Lagergren J. Bergestrom R. Lindgren A. Nyren O. (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825–831.
20. Lind T. Havelund T. Carlsson R. Anker-Hansen O. Glise H. Hernqvist H. et al (1997) Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 32: 974–979.
21. Mainie I. Tutuian R. Shay S. Vela M. Zhang X. Sifrim D. et al (2006) Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: A multicentre study using combined ambulatory impedance pH monitoring. Gut 55: 1398–1402.
22. Malfertheiner P. Fass R. Quigley E. Modlin I. Malagelada J. Moss R. et al (2006) Review article: From gastrin to gastro-oesophageal reflux disease – a century of acid suppression. Aliment Pharmacol Ther 23: 683–690.
23. Mattox H. Richter J. (1990) Prolonged ambulatory esophageal pH monitoring in the evaluation of gastroesophageal reflux disease. Am J Med 89: 345–356.
24. Peghini P. Katz P. Castell D. (1998) Imipramine decreases oesophageal pain perception in human male volunteers. Gut 42: 807–813.
25. Savarino E. Pohl D. Zentilin P. Dulbecco P. Sammito G. Sconfienza L. et al (2009) Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58: 1185–1191.
26. Savarino E. Zentilin P. Tutuian R. Pohl D. Casa D. Frazzoni M. et al (2008) The role of nonacid reflux in NERD: Lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 103: 2685–2693.
27. Shay S. Tutuian R. Sifrim D. Vela M. Wise J. Balaji N. et al (2004) Twenty-four hour ambulatory simultaneous impedance and pH monitoring: A multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 99: 1037–1043.
28. Sifrim D. Castell D. Dent J. Kahrials P. (2004) Gastro-esophageal reflux monitoring: Review and consensus report on detection and definition of acid, non-acid and gas reflux. Gut 53: 1024–1031.
29. Smout A. (1997) Endoscopy negative acid reflux disease. Aliment Pharmacol Ther 11: 81–85.
30. Tack J. Broekaert D. Coulie B. Fischler B. Janssens J. et al (2003) Influence of the selective-serotonin reuptake inhibitor paroxetine on gastric sensorimotor function in humans. Aliment Pharmacol Ther 17: 603–608.
31. The Rome II International Working Teams (2000) Functional heartburn. In: Drossman, D., Corazziari, E., Talley, N., Thompson, W. and Whitehead, W. (eds) Rome II: The Functional Gastrointestinal Disorders, 2nd edn. Lawrence: Allen Press Inc., pp. 275–278.
32. Vela, M., Camacho-Lobato, L., Srinivasan, R., Tutuian, R., Katz, P. and Castell, D. (2001) Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120: 1599–1606.
33. Vela M. (2009) Non-acid reflux: Detection by multichannel intraluminal impedance and pH, clinical significance and management. Am J Gastroenterol 104: 277–280.
34. Viazis N. Keyoglou A. Kanellopoulos A. Karamanolis G. Vlachogiannakos J. Triantafyllou K. et al (2011) Selective-serotonin reuptake inhibitors for the treatment of hypersensitive esophagus. A placebo controlled study using esophageal pH-impedance monitoring. Am J Gastroenterol in press.